The Science of

Gubra enables you to progress your preclinical pharmacology development for metabolic disorders with more certainty than any other research partner


Benefit from our extensive NASH know-how and test your compound in our validated DIO mouse model of NASH.


Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

Diabetic complications

Check out our novel rodent models of diabetic nephropathy and diabetic cardiomyopathy.


Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

“Gubra is easy to work with – less paperwork, valuable scientific input, flexible project management as well as clear and proactive communication.”

Jim Trevaskis
Principal Scientist, Head of In Vivo Pharmacology, Cardiovascular & Metabolic Diseases | MedImmune

“When it comes to working with Gubra, I highly appreciate the strong scientific involvement and curiosity that permeates our collaborations. I cannot ask for a stronger partner in our human physiology and clinical research projects.”

Filip Knop
MD, PhD, Director of Center for Diabetes Research | Gentofte Hospital, University of Copenhagen

“The long term experience and the deep scientific competence of Gubra partners adds value to the studies and is a guaranty for trustworthy results.“

Dr. Michael Mark
Vice President | Boeringer Ingelheim


Gubra now offers state-of-the art 3D imaging technologies to visualize pathogenesis and compound distribution in whole organs with single cell resolution.
See the visualization and read more

Press Release

Find out more about our second partner program with Boeringer Ingelheim Pharma. 

Read more


We are always looking for talent. Check out our open positions here.

Careers at Gubra


Hørsholm Kongevej 11B
2970 Hørsholm
+45 3152 ­2650